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Background: Owing to the rarity of sex cord tumor with annular tubules (SCTAT), it is difficult to recognize SCTAT
clinically and there is no standard treatment. The aim of our study was to investigate the treatment outcomes and
prognosis of patients with ovarian SCTAT.
Methods: A cohort of 13 patients with SCTAT diagnosed and treated in Peking Union Medical College Hospital was
studied. Data on clinicopathological characteristics, treatment, and prognosis were retrospectively reviewed and analyzed.
Results: SCTAT accounted for 1.4% of ovarian sex cord stromal tumors, with an average onset age of 22.6 years. All
patients presented with menstrual disturbances or isosexual precocity at disease onset. Initial surgery was unilateral
salpingo-oophorectomy in 11 cases. Recurrence rate was 46.2%, and 38.5% of patients experienced multiple recurrences.
The disease free interval gradually shortened with increasing numbers of recurrences. Recurrent tumors were mostly
ipsilateral to the primary tumor and located in retroperitoneum. Surgery remained the main treatment for recurrent cases.
Serum estradiol and progesterone levels usually elevated at disease onset, decreased dramatically after operation, and
they elevated again with the development of recurrence. The median progression-free survival (PFS) was 97.8 months,
and the 1-year and 5-year PFS were 92% and 67%, respectively. Five-year overall survival (OS) was 100%.
Conclusions: Unilateral salpingo-oophorectomy is a feasible treatment for primary SCTAT cases with intact capsules and
without PJS. Complete tumor resection is suggested for recurrent cases and long-term follow-up is strongly recommended.
Despite the high risk of recurrence, SCTAT prognosis is relatively favorable.
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Sex cord tumor with annular tubules (SCTAT) is a rare
and distinctive ovarian sex cord-stromal tumor (SCST),
accounting for approximately 2.3% of SCSTs [1]. The
predominant component of this tumor has intermediate
morphologic features between granulosa cell tumors and
Sertoli cell tumors and focal differentiation into either of
these tumor types may occur [2]. In 1970, Scully first de-
scribed this distinctive tumor [3], and a series of case re-
ports have since been published. The most notable is a* Correspondence: shenkeng@vip.sina.com
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unless otherwise stated.review of 74 SCTAT cases in 1982 [2]. They demon-
strated clinical and pathological findings and their asso-
ciations with Peutz–Jeghers syndrome (PJS). Among
these cases, 36.5% were associated with PJS and tumors
in these patients were usually benign, multifocal, bilat-
eral, calcified, and very small or even microscopic in
size. Tumors in patients without PJS (sporadic SCTAT)
were unilateral, large, and 21.9% cases were clinically
malignant [2]. However, most literature on SCTAT was
case reports [4-11] and there exists a serious lack of re-
ports with larger samples. Owing to its rarity, it is diffi-
cult to recognize SCTAT clinically, and there is no
agreed-upon management. In the present study, we re-
ported a cohort of 13 SCTAT cases and aimed to investi-
gate the treatment outcomes and prognosis.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study population
A total of 936 SCST cases were registered at Peking Union
Medical College Hospital (PUMCH) from 1968 to 2014.
Thirteen patients with SCTAT were diagnosed and treated
at the same period (1.4%). These cases were retrospectively
collected and reviewed by searching the ovarian tumor
database. The study was approved by the ethics committee
in Peking Union Medical College Hospital, Beijing, People’s
Republic of China. Of the 13 patients with SCTAT, eight
cases were treated for primary disease and five cases were
referred from other hospitals because of recurrence after
unilateral salpingo-oophorectomy. The following informa-
tion was collected: age, parity, complaint, clinical features,
imaging findings, tumor markers, sex hormone levels,
treatment modalities, and previous treatment records. The
diagnosis of SCTAT was confirmed by histopathology and
reviewed by two independent pathologists. The slides of
original ovarian tumors in patients with recurrence were
reviewed by pathologists in our hospital.
Treatment protocol
For patients with primary SCTAT, treatment in our hos-
pital was mainly unilateral salpingo-oophorectomy. For pa-
tients with recurrent SCTAT, complete recurrent tumor
resection (RTR) was the main treatment of choice. After
surgical treatment, patients with large tumors (≥30 cm) or
recurrences were treated with postoperative adjuvant
chemotherapy. Three cycles of standard combination
chemotherapy regimens (PEB—cisplatin 30–35 mg/m2,
intravenous drip, day 1–3; VP16 100 mg/m2, intravenous
drip, day1–3; and bleomycin 15 mg/m2, intramuscular,
days 2, 9, and 16; or PVB—cisplatin 30–35 mg/m2, intra-
venous drip, day 1–3; vinblastin 1–1.5 mg/m2, intravenous
drip, day 1–2; and bleomycin 15 mg/m2, intramuscular
days 2, 9, and 16) were given as the main adjuvant chemo-
therapy. Chemotherapy was repeated every 3 weeks. PEB
or PVB regimen with full dosage, adequate cycles, and
strict adherence was considered as standard chemotherapy.
Follow-up
All patients had regular follow-up after treatment, in-
cluding clinical examination, tumor marker (e.g., sex
hormones) measurements, and imaging tests at least
every 3 months during the first year following treatment
and at gradually increasing intervals thereafter. Follow-
up duration was defined from the day of initial surgery
to the last visit or death. Disease recurrence was defined
if clinical and/or imaging examinations demonstrated
visible disease or histopathology-confirmed diagnosis of
SCTAT after a documented disease-free interval follow-
ing initial therapy or after a documented complete re-
sponse to therapy. Progression-free survival (PFS) was
defined as the time from the date of initial surgery tothe date of disease progression or recurrence. Overall
survival (OS) was defined as the time from the date of
initial surgery to the date of death or last visit.
Statistical analysis
Data from the present study were analyzed using standard
descriptive statistics (e.g., frequencies and percentages).
Comparisons of frequency distribution between categorical
variables were made using the Chi-square test or Fisher’s
exact test. Life table was used for survival analysis. Two
sided P-values < 0.05 were considered statistically signifi-
cant. Statistical analysis was conducted with SPSS 17.0 soft-
ware (IBM Corp, Armonk, NY, USA).
Results
Clinical features
Thirteen patients with SCTAT were identified from 936
SCST cases admitted in PUMCH at the same period,
accounting for 1.4% of SCST cases. Clinicopathologic
features, treatment modalities, and follow-up data are
presented in Table 1. The average onset age of the 13
patients was 22.6 ± 12.1 years old (range 5–39 years)
and 6 (46.2%) patients were ≤18 years old. All patients
had menstrual disturbances at disease onset, including
seven patients presenting with amenorrhea, three pa-
tients presenting with prolonged menstrual bleeding,
and three patients presenting with isosexual precocity
(breast budding, pubic hair growth, and early menarche
before the age of 8 years old) at the age of 8, 6, and
5 years old, respectively. Besides, before the presenta-
tion of amenorrhea, three patients had irregular men-
strual cycles and four patients had irregular menstrual
bleeding with prolonged menses. Patients with recur-
rent tumors also presented with menstrual distur-
bances. Abdominal or pelvic masses were found in all
patients by physical examinations and/or with imaging
tests such as ultrasonography, computed tomography
(CT), or positron emission tomography (PET)-CT scan
(Figure 1A).
Of the 13 patients with SCTAT, eight cases were treated
for primary tumors and five cases were referred from other
hospitals for recurrent tumors. One case (case 5) had pig-
mentation of the oral mucosa, but had no documentation
of gastrointestinal polyps. None of the other patients had
documented PJS presentations. In eight cases with primary
tumors, only two pediatric patients (case 9, 13) had a pre-
operative diagnosis of SCTAT based on biopsy of ovarian
tumor. In the five recurrent cases referred from other hos-
pitals, only case 11 was diagnosed with SCTAT histopatho-
logically at the referring hospitals.
Table 2 compares the clinicopathologic features and
treatment modalities between patients with and without
recurrence. Patients with age < 18 years old, bilateral ovar-
ian tumors, postoperative chemotherapy, or cytoreductive










Onset Admission Surgery Chemo Month Outcome
1 18 26 aRSO Right:- aTAH + LSO +
RTR + LN biopsy
PVB*3 2 - 146 DOD






3 Chemo: PVB*4; aRTR +
RPL + RT
179 PR
3 15 15 No Right:30 cm aRSO nitrosourea 0 - 84 CR
4 8 8 No Left:9 cm aLSO + biopsy of
right ovary
- 0 - 48 CR





- 0 - 24 CR
6 21 29 aRSO Right:24 cm aTAH + LSO +
RTR + omentum
PVB*2 3 aRTR;RT 143 PR
7 18 20 aLSO; RTR +
RPL + RT +
Chemo
Left:20 cm aRTR + RPL + LND PEB*3 2 - 26 CR
8 39 39 No Right:5 cm bRSO and biopsy
of left ovary
- 0 - 55 CR
9 6 6 aBiopsy of
ovary
Left:8 cm aLSO - 0 - 63 CR
10 39 39 No Right:12 cm aTAH + BSO +
LND + omentum
PEB*3 0 - 107 CR
11 29 30 aLSO Left:6 cm aRTR + RPL + LND PEB*3 1 - 21 CR
12 34 34 No Right:12+cm bCystectomy - 3 aRSO + RTR +
omentum + appendix;
RTRa + chemo; RTRa
51 PR
13 5 5 No Left:8 cm bBiopsy of ovary;
bLSO
- 0 - 20 CR
Note: Chemo, chemotherapy; RSO, right salpingo-oophorectomy; TAH, total abdominal hysterectomy; LSO, left salpingo-oophorectomy; RTR, recurrent tumor
resection; LN, lymph nodes; RPL, retroperitoneal lymphadenectomy; DOD, died of disease; 5-Fu, 5-fluorouracil; TSPA, Thiotepa; PVB, cisplatin + vinblastine +
bleomycin; RT, radiotherapy; PR, partial remission; CR, complete remission; PEB, cisplatin + etoposide + bleomycin; BSO, bilateral salpingo-oophorectomy; LND,
lymph node dissection; alaparotomy; blaparoscopy.
Qian et al. BMC Cancer  (2015) 15:270 Page 3 of 8surgery (CRS) did not experience recurrence during follow-
up. However, no statistically significant difference was
found in clinicopathologic features and treatment mo-
dalities between patients with and without recurrence
(P > 0.05).
Treatment
Of the eight patients with primary tumors, six (75%)
underwent unilateral salpingo-oophorectomy and biopsy
of the contralateral ovary was performed in three of
them (case 4, 5, 8). The other two patients were treated
respectively with laparoscopic ovarian cystectomy (case 12)
and CRS (case 10; including total hysterectomy, bilateral
salpingo-oophorectomy, omentectomy, and bilateral pelvic
lymphadenectomy) because a SCTAT diagnosis with the
possibility of malignancy was made by intraoperative fro-
zen section examination. Pelvic lymph nodes were negative
in case 10. Another five cases referred from other hospitalsunderwent unilateral salpingo-oophorectomy previously as
initial therapy in the referring hospitals.
There were a total of 14 recurrences in six recurrent
patients. RTR (Figure 1C and D) was performed for five
recurrences in four patients. CRS including total hyster-
ectomy, contralateral salpingo-oophorectomy, and RTR
was performed in three patients. CRS with fertility preser-
vation was performed for three recurrences in one patient
(case 12). Four patients underwent lymphadenectomy, of
whom two underwent ipsilateral pelvic and para-aortic
lymphadenectomy (case 2,11), case 7 underwent bilateral
pelvic and para-aortic lymphadenectomy and case 1 under-
went pelvic lymph node biopsy. Positive pelvic lymph
nodes were found in three patients (case 1, 2, 7) and posi-
tive para-aortic lymph nodes were found in three patients
(case 2, 7, 11). After surgical treatment, all recurrent
patients were treated by adjuvant chemotherapy and
two patients were treated by radiotherapy owing to
supraclavicular lymph node metastasis. Chemotherapy
Figure 1 PET-CT scan and macroscopic findings in a recurrent patient (case 11). (A) PET-CT scan before treatment; a black arrow points to the
metastatic tumor in the left portion of the fourth lumbar vertebra. (B) PET-CT scan after treatment. (C) and (D) show the retroperitoneal tumor
fused by several para-aortic lymph nodes.
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two patients, respectively.
In patients with primary tumors, only two patients were
treated by surgery combined with chemotherapy, case 3
for a large tumor (30 cm in diameter; nitrosourea) and
case 10 for a SCTAT diagnosis with the possibility of ma-
lignancy (three cycles of PEB). For recurrent patients, PEB
or PVB was the main chemotherapy regimen and was ad-
ministered in five patients (case 1, 2, 6, 7, 11). One pa-
tient (case12) with multiple recurrences and extensive
metastasis accepted chemotherapy regimens including
PV (cisplatin + vinblastine), TC (paclitaxel + carbopla-
tin), and PT (cisplatin + paclitaxel).
Histopathological characteristics
All primary tumors were confined to ovaries and had in-
tact capsules, with an average diameter of 12.1 cm
(range 5.0–30.0 cm). Tumors originated from the left
ovary in six cases, right ovary in six cases, and bilateral
ovaries in only one case (case 5) with a microscopic
tumor in the left ovary and a 13 cm tumor in the right
ovary. All the pediatric patients (<10 years old) had poly-
cystic tumors filled with clear yellow fluid and associatedwith multiple yellow nodules ranging in size from 0.5 to
1.0 cm inside the cyst (Figure 2). Tumors in other patients
including recurrent cases had yellow section surfaces.
Recurrent tumors were mostly ipsilateral to the primary
tumor and located mainly in retroperitoneum, such as pel-
vic lymph nodes, para-aortic lymph nodes, and other sites
in retroperitonium. Besides, supraclavicular lymph node
metastasis was found in three patients (case 2, 6, 11). Ex-
tensive metastasis in the abdominal and pelvic cavity was
found in two cases (case 7, 11) and recurrent tumors were
also mainly ipsilateral to the primary tumor. No metastasis
was found in the uterus and during the long-term follow-
up no metastasis was found in the contralateral ovary.
The typical SCTAT structure is characterized by cir-
cumscribed columnar epithelial nests composed of
ring-shaped tubules, which are encircled by hyalinized
basement membrane-like material (Figure 3) [12]. No
calcification was seen in tumor tissues. Mitotic count
was only reported in two patients (case10, 12), and var-
ied from 1 to 3 per 10 high power fields (HPF). Histo-
pathological diagnosis of endometrium was made in
seven patients, including three cases of glandular atro-
phy with decidual change in the stroma, three cases of
Table 2 Comparison of clinicopathologic features and
treatment modalities between patients with and without
recurrence (Chi-square test)
Parameters Recurrence P
valueaYes ( 6 cases) No (7 cases)
age
≥18 years 6 (66.7%) 3 (33.3%) 0.07
<18 years 0 (0%) 4 (100%)
Side of tumor
left 3 (50%) 3 (50%) 0.52
right 3 (50%) 3 (50%)
bilateral 0 (0%) 1 (100%)
Chemotherapyb
Yes 0 (0%) 2 (100%) 0.46
no 6 (54.5%) 5 (45.5%)
surgery
USO 5 (45.5%) 6 (54.5%) 0.25
Cystectomy 1 (100%) 0 (0%)
CRS 0 (0%) 1 (100%)
Ovarian tumor size
>10 cm 2 (40%) 3 (60%) 1.00
≤10 cm 4 (50%) 4 (50%)
Note: USO, unilateral salpingo-oophorectomy; CRS, cytoreductive surgery,
predominantly including total hysterectomy, bilateral salpingo-oophorectomy,
omentectomy and pelvic lymphadenectomy; aFisher’s exact test. brefers to
adjuvant chemotherapy after initial surgical treatment.
Figure 3 Pathologic findings in case 10 (H&E staining × 400
magnification). The tumor shows circumscribed columnar epithelial
nests and multiple tubules encircling hyalinized basement
membrane-like material.
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endometrium with decidual change in the stroma.
Immunohistochemical staining was made in seven cases;
a 100% (7/7) positive rate was seen for alpha-inhibin, 80%
(4/5) for calretinin, 66.7% (2/3) for CD99, 50% (1/2) for
Melan-A, and 66.7% (2/3) for AE1/AE3. Tumors were
negative for Chromogranin A (CgA; 0/3), synaptophy-
sin (Syn; 0/3), epithelial membrane antigen (EMA; 0/
4), p53 (0/2), S-100 (0/2), CD10 (0/1), Wilms’ tumor
gene 1 (WT-1; 0/1), and placental alkaline phosphataseFigure 2 Macroscopic findings in a 5-year-old patient (case 13). (A) Multilo
(B) The sectioned surface of the tumor showed clear yellow fluid and mult(PLAP; 0/1). Proliferation-associated antigen Ki67 ranged
from 2% to 30%.Tumor markers and sex hormones
Serum CA125 levels were tested in seven cases and only
case 12 had abnormal CA125 levels after the second recur-
rence with a maximum level of 211 U/mL. No abnormality
was found in other tumor markers, including CEA (0/4),
AFP (0/6), CA199 (0/4), CA242 (0/2), CA153 (0/2), and
CA724 (0/1).
Levels of estradiol (Figure 4) and progesterone (Figure 5)
were only monitored dynamically in five patients, respect-
ively. Both estradiol and progesterone levels decreased
markedly when tumors were removed and elevated dramat-
ically with the presence of recurrence. Levels of testoster-
one were monitored dynamically in six patients. However,
only one patient (case 10) had elevated testosterone level
(64 ng/dL) at disease onset and decreased to 5.4 ng/dL after
surgical treatment. Other hormone levels, such as prolactin,cular cystic tumor ranging in size from 0.5 to 1.0 cm inside the cyst.
iple yellow nodules inside the cyst wall.
Figure 4 Preoperative and post-operative estradiol levels in five patients with SCTAT. Pre = preoperative test of estradiol; post-n = nth test of
estradiol after initial treatment in our hospital; R = recurrence; Post-O = post-operation after recurrence.
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(FSH), did not show obvious tendencies.
Follow-up
During follow-up, six (46.2%) patients experienced re-
currence. There were a total of 14 recurrences in these
six patients. Multiple recurrences (range 2–3) were
observed in five (38.5%) patients. Mean duration from
initial surgical treatment to first recurrence, from first
recurrence to second recurrence, and from second re-
currence to third recurrence were 45.5 months (range
7–108 months), 29.2 months (range 5–77 months), and
18.7 months (range 12–30 months), respectively. TheFigure 5 Preoperative and post-operative progesterone levels in five patie
test of progesterone after initial treatment in our hospital; R = recurrence; Pmost notable case was one patient (case 12) who deve-
loped three recurrences and extensive metastasis in the
abdominal and pelvic cavity, including omentum, dia-
phragm, peritoneum, retroperitoneum, and abdominal
wall at 9, 19, and 31 months, respectively, after laparo-
scopic ovarian cystectomy in our hospital. Eventually
she achieved partial remission (PR) and was alive with
disease after three fertility-sparing CRS surgeries.
Mean follow-up duration was 74.5 months (range
20–179 months). The median PFS was 97.8 months,
and the 1-year and 5-year PFS were 92% and 67%, re-
spectively. The 5-year OS was 100%. In our study, seven
patients with primary disease achieved complete remissionnts with SCTAT. Pre = preoperative test of progesterone; post-n = nth
ost-O = post-operation after recurrence.
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treatment and two recurrent patients also achieved CR
without recurrence after RTR combined with PEB or PVB
chemotherapy. Three recurrent patients achieved PR and
were alive with disease after surgery and/or radiotherapy.
Case 1 died of progressive disease and cachexia after two
recurrences 12 years after treatment.
Discussion
SCTAT is a rare SCST accounting for only 1.4% of SCSTs
in our study. SCTAT diagnosis is usually based on patho-
logical examination of the tumor and typical clinical pre-
sentations are usually consistent with a hormone-secreting
tumor, resulting in precocious puberty in children or men-
strual disturbances, such as amenorrhea, in reproductive
age women. Some researchers have demonstrated that
SCTAT secretes not only estradiol, but also progesterone
[12-14]. Our study also found endometrial decidual change
in the stroma consistent with the progesterone effect in
four patients. However, preoperative or even intraoperative
SCTAT diagnosis is rather difficult. In our study, preopera-
tive SCTAT diagnosis was only made in two pediatric pa-
tients based on ovarian tumor biopsy, both of whom were
highly suspected of physiological cysts instead of ovarian
tumors. Thus, biopsy was chosen to reduce the damage to
ovarian tissue. However, this results in disruption of the
capsule and may change prognosis of ovarian tumors. It
turns out to be prudent to perform biopsy in patients with
ovarian mass.
There is no standard treatment protocol for patients
with SCTAT because of its rarity. Initial management
for patients with SCTAT is surgery. It is very important
to preserve fertility because most cases occur in adoles-
cents or in reproductive age women. In our study, the
median onset age was 22.6 years, which is similar to a
previous report [2]. Tumors in SCTAT patients without
PJS are usually unilateral and most patients can be diag-
nosed at early stages owing to hormone-related symp-
toms. Thus, fertility-sparing surgery is feasible for those
young patients. However, ovarian cystectomy is not sug-
gested because of the high rate of recurrence. In our
study, only one patient was treated with ovarian cys-
tectomy and experienced three recurrences and ex-
tensive metastasis in the abdominopelvic cavity within
31 months after initial surgery. Unilateral salpingo-
oophorectomy is feasible for patients with an intact cap-
sule and tumor confined to one ovary. In our study, six
patients achieved CR without recurrence after treatment
with unilateral salpingo-oophorectomy. Wedge section
or biopsy of the contralateral ovary is not a routine pro-
cedure, but it should be considered, especially for pa-
tients with suspected lesion in the contralateral ovary.
Because patients with PJS usually have bilateral ovarian
tumors [2], it is prudent to maintain fertility for patientswith any manifestation of PJS, such as hamartomatous
polyps of the gastrointestinal tract, mucocutaneous mel-
anin pigmentation, and various neoplasms. Even if the
tumor is confined to one ovary, wedge section or biopsy
of the contralateral ovary is strongly recommended for
patients with PJS. Moreover, in our study, no metastasis
was found in the contralateral ovary or uterus during
follow-up. For patients without fertility desires, the ef-
fects of contralateral ovary resection and/or hysterec-
tomy on prognosis should be further investigated.
Different from epithelial ovarian cancer, surgery is still
the main treatment of choice for patients with recurrent
SCTAT. Recurrent tumors tend to be retroperitoneal
and can be detected and located by imaging tests, such
as ultrasonography, CT, or PET-CT scan (Figure 1A).
Preoperative evaluation is very important for recurrent
SCTAT. PET-CT scan is a favorable method for the
evaluation of tumor size, numbers, location of recurrent
tumors, and the therapeutic effect (Figure 1A and B).
Fertility-sparing surgery can be still considered for patients
with no involvement of contralateral ovary and uterus. In
our study, fertility-sparing surgery with complete RTR was
performed in three patients. Patients with multiple recur-
rences can also achieve CR or PR after RTR or CRS.
Because the majority of recurrent tumors located in
retroperitoneum, particularly in pelvic lymph nodes ipsi-
lateral to the primary tumor and/or para-aortic lymph
nodes, ipsilateral pelvic and para-aortic lymphadenec-
tomy may be considered to reduce recurrence. In our
study, only one patient (case 10) underwent bilateral pel-
vic lymphadenectomy as part of initial treatment and
achieved CR afterwards. Two recurrent patients who
underwent ipsilateral pelvic and para-aortic lymphade-
nectomy achieved CR (case 11) and PR (case 2), re-
spectively. To date, there are only a few reports of
lymphadenectomy or lymph node biopsy in patients with
SCTAT and they lacked long-term follow-up data [7,9,15].
The role of lymphadenectomy, especially ipsilateral pelvic
and para-aortic lymphadenectomy, in the treatment of
SCTAT patients should be further investigated.
The effects of chemotherapy and radiotherapy are not
clear. Although four patients (case 3, 10, 7, 11) achieved
CR after surgery combined with chemotherapy and two
patients (case 2, 6) achieved PR after radiotherapy with/
without surgery in our study, chemotherapy or radio-
therapy cannot completely protect patients from recur-
rence. Further studies are needed to confirm the effects
of chemotherapy and radiotherapy.
SCTAT was thought to be an ovarian tumor with low
malignant potential and late recurrence [12]. 21.9% of
cases were clinically malignant in patients with sporadic
SCTAT [2], and only few PJS-associated SCTAT cases
with malignant behavior have been reported [7]. In our
study, recurrence rate reached 46.2% and multiple
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indicated the malignant potential of SCTAT. Although
the recurrence rate is high, the prognosis of patients with
SCTAT is relatively favorable. Most recurrences were con-
trolled well by surgeries and/or adjuvant therapy, and the
1-year and 5-year PFS were 92% and 67%, respectively.
The median PFS time was 97.8 months, but the disease
free interval gradually shortened with increasing numbers
of recurrences. The 5-year OS was 100%.
Although SCTAT prognosis is relatively favorable, the
risk of recurrence is still very high. Long-term follow-up is
essential for patients with SCTAT. Our results demon-
strated that recurrent patients would present with men-
strual disturbances and pelvic or abdominal masses again
at the time of recurrence. Thus, careful history taking and
physical examination combined with imaging tests can be
used as monitoring methods. In addition, both serum es-
tradiol and progesterone can be used as tumor markers
during follow-up. Elevated serum inhibin level was also re-
ported in patients with SCTAT by several researchers
[9,16] and immunohistochemical staining in our patients
demonstrated that the most common marker was alpha-
inhibin, with a positive rate of 100% (7/7). Thus, serum in-
hibin may also be used for follow-up.
Conclusions
Unilateral salpingo-oophorectomy is feasible for primary
patients with intact capsules and without PJS. Complete
tumor resection is recommended for recurrent cases
and fertility-sparing surgery can be considered for recur-
rent patients with no involvement of the contralateral
ovary and uterus. Despite the high risk of recurrence,
SCTAT prognosis is relatively favorable. Long-term
follow-up is strongly recommended. Further studies are
needed to confirm the effects of pelvic and para-aortic
lymphadenectomy, chemotherapy, and radiotherapy in
the treatment of patients with SCTAT.
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